Scratching the Surface of Immunotherapeutic Targets in Neuroblastoma

Slides:

Advertisements

Similar presentations

T-bet+ Treg Cells Undergo Abortive Th1 Cell Differentiation due to Impaired Expression of IL-12 Receptor β2 Meghan A. Koch, Kerri R. Thomas, Nikole R.

Advertisements

Maintaining Cell Identity through Global Control of Genomic Organization Gioacchino Natoli Immunity Volume 33, Issue 1, Pages (July 2010) DOI: /j.immuni

Evolution of the Cancer Stem Cell Model Antonija Kreso, John E. Dick Cell Stem Cell Volume 14, Issue 3, Pages (March 2014) DOI: /j.stem

ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics Carlos L. Arteaga, Jeffrey A. Engelman Cancer Cell Volume.

Human Brown Adipose Tissue Sven Enerbäck Cell Metabolism Volume 11, Issue 4, Pages (April 2010) DOI: /j.cmet Copyright © 2010.

Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors Sara Charmsaz, Andrew M. Scott,

Chemotherapy and Cancer Stem Cells

T-ALL: Home Is where the CXCL12 Is

Chapter 08 The T Cell Receptor: Proteins and Genes

Volume 7, Issue 3, Pages (March 2005)

Cancer: Inappropriate Expression of Stem Cell Programs?

Man's Best Friend: Utilizing Naturally Occurring Tumors in Dogs to Improve Chimeric Antigen Receptor T-cell Therapy for Human Cancers Melinda Mata, Stephen.

Advances in Specific Immunotherapy for Prostate Cancer

Engineering Natural Killer Cells for Cancer Immunotherapy

Scratching the Surface of Immunotherapeutic Targets in Neuroblastoma

Intravascular Survival and Extravasation of Tumor Cells

Kenneth L. Scott, Scott Powers Cancer Cell

Metastasis gets site specific

Influenza Vaccines: Challenges and Solutions

Mutant p53 gain of function: The NF-Y connection

Radiotherapy Complements Immune Checkpoint Blockade

Ana Magalhães, Henrique O. Duarte, Celso A. Reis Cancer Cell

Not So Fast: Cultivating miRs as Kinks in the Chain of the Cell Cycle

Cellular Origin of Androgen Receptor Pathway-Independent Prostate Cancer and Implications for Therapy W. Nathaniel Brennen, John T. Isaacs Cancer Cell

Michael W.M. Kühn, Scott A. Armstrong Cancer Cell

Ada G. Blidner, Karina V. Mariño, Gabriel A. Rabinovich Immunity

Biomarkers in Cancer Immunotherapy

Tumor Evolution: A Problem of Histocompatibility

Tailor-Made Renal Cell Carcinoma Vaccines

Michael W.M. Kühn, Scott A. Armstrong Cancer Cell

DAISY: Picking Synthetic Lethals from Cancer Genomes

Tipping the Balancing ACT

Volume 20, Issue 1, Pages (January 2017)

Can Treating the SYK Cell Cure Leukemia?

Laurence Zitvogel, Guido Kroemer Cancer Cell

Octavio Ramilo, Asunción Mejías Cell Host & Microbe

Cellular Origin of Androgen Receptor Pathway-Independent Prostate Cancer and Implications for Therapy W. Nathaniel Brennen, John T. Isaacs Cancer Cell

Unraveling the Pros and Cons of Interferon-γ Gene Regulation

PU.1 Takes Control of the Dendritic Cell Lineage

Coordinate Transcriptional Regulation by ERG and Androgen Receptor in Fusion- Positive Prostate Cancers Yu Chen, Charles L. Sawyers Cancer Cell Volume.

Engineering Natural Killer Cells for Cancer Immunotherapy

Neuroblastoma and Ewing's Sarcoma Associated with ROR1 Expression Can Be Effectively Targeted with NK Cells Modified to Express an Anti ROR1 Chimeric.

Gliomas “Dope Up” for Growth

Shannon M. Kahan, Allan J. Zajac Immunity

MicroRNAs and Parallel Stem Cell Lives

The p27Kip1 tumor suppressor gene: Still a suspect or proven guilty?

Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors Sara Charmsaz, Andrew M. Scott,

Characterizing the Killer Colorectal Carcinomas

Vismodegib Resistance in Basal Cell Carcinoma: Not a Smooth Fit

Mismatch Repair-Deficient Cancers Are Targets for Anti-PD-1 Therapy

Targeting Cancer Stemness in the Clinic: From Hype to Hope

Kabir A. Khan, Robert S. Kerbel Cancer Cell

Ricardo U. Sorensen, MD, Luke A. Wall, MD

Figure 1 Mechanisms of action of immunotherapy modalities

Kenneth L. Scott, Scott Powers Cancer Cell

Shifting the Evolving CAR T Cell Platform into Higher Gear

Proteins in Plant Brassinosteroid Signaling

Robbie G. Majzner, Sabine Heitzeneder, Crystal L. Mackall Cancer Cell

Bispecific Antibodies Against HIV

Immune response modifiers in the treatment of asthma: A PRACTALL document of the American Academy of Allergy, Asthma & Immunology and the European Academy.

Molecular Therapy Volume 21, Pages S247-S248 (May 2013)

Sticking It to Cancer with Molecular Glue for SHP2

TFIID and MYB Share a Therapeutic Handshake in AML

Releasing the Brakes on Cancer Immunotherapy

There's a Time and a Place for MYCN

Human cancer immunotherapy strategies targeting B7-H3 A, blockade of B7-H3 with blocking mAbs neutralizes inhibitory signaling in its unidentified receptor(s)

Sensing Bad: Are Co-stimulatory CAR-Expressing γδ T Cells Safer?

Volume 12, Issue 6, Pages (December 2007)

Targeting Protein Stability with a Small Molecule

Stable IL-10: A New Therapeutic that Promotes Tumor Immunity

Presentation transcript:

Scratching the Surface of Immunotherapeutic Targets in Neuroblastoma Clare F. Malone, Kimberly Stegmaier Cancer Cell Volume 32, Issue 3, Pages 271-273 (September 2017) DOI: 10.1016/j.ccell.2017.08.011 Copyright © 2017 Elsevier Inc. Terms and Conditions

Figure 1 Identifying and Therapeutically Targeting Differentially Expressed Cell Surface Proteins Bosse et al. use gene expression data to identify differentially expressed genes in neuroblastoma relative to normal tissue and filter for predicted cell surface epitopes. Although they use an antibody-drug conjugate (ADC) approach, cell surface proteins can also be targeted using antibody-dependent cell-mediated cytotoxicity (ADCC), engineered chimeric antigen receptor (CAR) T cells, or bispecific antibodies recognizing the cell surface epitope on a tumor cell, as well as a cell surface epitope on an immune cell, such as a T cell or NK cell. Cancer Cell 2017 32, 271-273DOI: (10.1016/j.ccell.2017.08.011) Copyright © 2017 Elsevier Inc. Terms and Conditions